300006.SHE Chongqing Lummy Pharmaceutical
- Market cap
- CNY 10.5B
- P/E
- -
- P/B
- 6.09x
- ROE
- -2.4%
- Dividend yield
- 0.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300006.SHE undervalued?
Graham numberThe Graham number of Chongqing Lummy Pharmaceutical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chongqing Lummy Pharmaceutical fundamental analysis
No fundamental analysis for Chongqing Lummy Pharmaceutical yet.
Chongqing Lummy Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The company was founded in 1999 and is headquartered in Chongqing, China.
Full company profileChongqing Lummy Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chongqing Lummy Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 990M | 1.28B | 1.56B | 1.86B | 1.58B | 1.23B | 885M | 896M | 796M | 769M | 701M |
| Gross Profit | 403M | 621M | 942M | 1.32B | 1.06B | 844M | 646M | 612M | 499M | 389M | 350M |
| Operating Income | -6.66M | 48.3M | 109M | -169M | -346M | -70.1M | -96.0M | 56.2M | -106M | -102M | -15.6M |
| EBITDA | 146M | 193M | 277M | 14.1M | -149M | -3.87M | 15.9M | 81.7M | -15.3M | -47.7M | -33.3M |
| Net Income | 6.98M | 55.6M | 98.0M | -155M | -327M | -101M | -68.7M | -8.93M | -87.8M | -135M | -40.9M |
| EPS | 0.01 | 0.07 | 0.12 | -0.19 | -0.40 | -0.10 | -0.07 | -0.01 | -0.08 | -0.13 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 2.48B | 2.74B | 3.14B | 3.50B | 3.15B | 2.93B | 3.05B | 2.89B | 2.86B | 2.57B | 2.50B |
| Total Liabilities | 810M | 1.02B | 1.42B | 1.85B | 1.92B | 715M | 870M | 769M | 972M | 806M | 765M |
| Shareholders' Equity | 1.63B | 1.69B | 1.70B | 1.56B | 1.17B | 2.16B | 2.12B | 2.08B | 1.88B | 1.76B | 1.72B |
| Cash & Short-term Investments | 183M | 214M | 315M | 437M | 545M | 559M | 846M | 836M | 1.07B | 926M | 903M |
| Total Debt | 531M | 556M | 881M | 1.25B | 1.16B | 195M | 365M | 243M | 388M | 379M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 126M | 61.4M | 226M | 231M | 225M | 108M | 57.1M | 81.5M | 185M | 61.3M | - |
| Capital Expenditure | 77.0M | 21.2M | 126M | 63.1M | 43.6M | 38.7M | 68.2M | 59.3M | 75.5M | 38.2M | 29.6M |
| Free Cash Flow | 48.7M | 40.2M | 100.0M | 168M | 181M | 69.6M | -11.1M | 22.2M | 110M | 23.2M | -27.3M |
| Ratios | |||||||||||
| ROE | 0.4% | 3.3% | 5.8% | -10.0% | -27.9% | -4.7% | -3.2% | -0.4% | -4.7% | -7.7% | -2.4% |
| ROA | 0.3% | 2.0% | 3.1% | -4.4% | -10.4% | -3.4% | -2.2% | -0.3% | -3.1% | -5.2% | -1.6% |
| Net Profit Margin | 0.7% | 4.3% | 6.3% | -8.3% | -20.6% | -8.2% | -7.8% | -1.0% | -11.0% | -17.5% | -5.8% |
| Debt to Equity | 0.33x | 0.33x | 0.52x | 0.80x | 0.99x | 0.09x | 0.17x | 0.12x | 0.21x | 0.22x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chongqing Lummy Pharmaceutical dividends
- Dividend yield
- 0.12%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 3, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 12.3M | 0.01 | - |
| 2024 | CNY 10.8M | 0.01 | - |
| 2023 | CNY 11.8M | 0.01 | - |
| 2022 | CNY 17.5M | 0.02 | - |
| 2021 | CNY 29.1M | 0.03 | - |
| 2020 | CNY 40.6M | 0.05 | - |
| 2019 | CNY 40.6M | 0.05 | - |
| 2018 | CNY 93.9M | 0.12 | 95.8% |
| 2017 | CNY 74.7M | 0.09 | 134.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 36:10 on May 24, 2016.
Who owns Chongqing Lummy Pharmaceutical
- Insiders 39.38%
- Institutions 3.48%
- Public & others 57.15%
- Shares outstanding 1.06B
- Free float 698M
Chongqing Lummy Pharmaceutical company profile
- Company name
- Chongqing Lummy Pharmaceutical
- Ticker
- 300006.SHE
- ISIN
- CNE100000H10
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 30, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 973
- Fiscal year end
- December
- Address
- Building B, Huangshan Avenue, Chongqing, China, 401121
- Phone
- 86 23 6730 0395
- Website
- cqlummy.com
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The company was founded in 1999 and is headquartered in Chongqing, China.
Chongqing Lummy Pharmaceutical management
5- Mr. Rongzhao QiuGeneral Manager · born 1994
- Ms. Wen LaiFinancial Director · born 1974
- Mr. Dan CuiDeputy GM, Secretary & General Counsel · born 1980
- Mr. Song LinDeputy GM & Director · born 1973
- Ms. Ruoyue WangDeputy GM & GM of Chemical Pharmaceutical Division · born 1959